Analysis of COVID-19 prevention and treatment in Taiwan (Review)

Authors

Yu-Jen Chiu, Division of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veteran General HospitalFollow
Jo‑Hua Chiang, Department of Nursing, Chung‑Jen Junior College of Nursing, Health Sciences and ManagementFollow
Chih-Wei Fu, Biomedical Technology and Device Research Laboratories, Industrial Technology Research InstituteFollow
Mann-Jen Hour, School of Pharmacy, China Medical UniversityFollow
Hai-Anh Ha, School of Pharmacy, China Medical UniversityFollow
Sheng-Chu Kuo, School of Pharmacy, China Medical UniversityFollow
Jen-Jyh Lin, Division of Cardiology, Department of Medicine, China Medical University HospitalFollow
Ching-Chang Cheng, Laboratory Animal Service Center, China Medical UniversityFollow
Shih‑Chang Tsai, Department of Biological Science and Technology, China Medical University,Follow
Yu‑Shiang Lo, Department of Medical Research, China Medical University Hospital, China Medical UniversityFollow
Yu‑Ning Juan, Department of Medical Research, China Medical University Hospital, China Medical UniversityFollow
Yih-Dih Cheng, School of Pharmacy, China Medical UniversityFollow
Jai-Sing Yang, Department of Medical Research, China Medical University Hospital, China Medical UniversityFollow
Fuu‑Jen Tsai, School of Chinese Medicine, College of Chinese Medicine, China Medical UniversityFollow

Abstract

Coronavirus disease 2019 (COVID‐19) has been spreading worldwide with a mind-boggling speed. According to a statement from World Health Organization (WHO), COVID-19 has infected more than six billions people and caused more than one and half million passing in the world. Based on previous experience with SARS, the Taiwanese government had decided to block viral transmission during its early stages. This review sums up the clinical characteristics, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) viral infection process, diagnostic methods, preventive strategy, and the executive proportions of COVID-19, as well as the name-based mask distribution system (NBMDS) in Taiwan. We also give a review of the conceivable sub-atomic pharmacologic systems against SARS-CoV-2 specialists and the blend of remdesivir (GS-5734), chloroquine (CQ), and hydroxychloroquine (HCQ). Lastly, we summarized the therapeutic agents against COVID-19 as mentioned by COVID-19 treatment guidelines. In this review, development of novel anti-SARS-CoV-2 viral agents, vaccines for COVID-19 therapy or an effective combination therapy can be expected based on all the information accumulated. Last but not least, we might want to stretch out our best respects to all medical providers in their worldwide battle against COVID-19.

Recommended Citation

Chiu, Yu-Jen; Chiang, Jo‑Hua; Fu, Chih-Wei; Hour, Mann-Jen; Ha, Hai-Anh; Kuo, Sheng-Chu; Lin, Jen-Jyh; Cheng, Ching-Chang; Tsai, Shih‑Chang; Lo, Yu‑Shiang; Juan, Yu‑Ning; Cheng, Yih-Dih; Yang, Jai-Sing; and Tsai, Fuu‑Jen (2021) "Analysis of COVID-19 prevention and treatment in Taiwan (Review)," BioMedicine: Vol. 11 : Iss. 1 , Article 1.
DOI: 10.37796/2211-8039.1185

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.